Anchor Capital Advisors LLC trimmed its position in McKesson Co. (NYSE:MCK – Free Report) by 5.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 126,692 shares of the company’s stock after selling 6,894 shares during the quarter. McKesson makes up approximately 2.1% of Anchor Capital Advisors LLC’s portfolio, making the stock its 4th biggest holding. Anchor Capital Advisors LLC owned approximately 0.10% of McKesson worth $72,203,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Synergy Asset Management LLC bought a new position in shares of McKesson in the fourth quarter worth approximately $32,000. MidAtlantic Capital Management Inc. bought a new position in shares of McKesson in the third quarter worth approximately $29,000. Crews Bank & Trust bought a new position in shares of McKesson in the fourth quarter worth approximately $33,000. RPg Family Wealth Advisory LLC bought a new position in shares of McKesson in the third quarter worth approximately $31,000. Finally, Creative Capital Management Investments LLC bought a new position in shares of McKesson in the fourth quarter worth approximately $44,000. 85.07% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In related news, CEO Brian S. Tyler sold 8,961 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $600.66, for a total value of $5,382,514.26. Following the completion of the sale, the chief executive officer now owns 69,625 shares of the company’s stock, valued at $41,820,952.50. This trade represents a 11.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Leann B. Smith sold 188 shares of the firm’s stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $609.59, for a total value of $114,602.92. Following the completion of the sale, the executive vice president now directly owns 1,051 shares of the company’s stock, valued at $640,679.09. The trade was a 15.17 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 19,268 shares of company stock valued at $11,536,378 over the last quarter. 0.11% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Read Our Latest Stock Report on MCK
McKesson Stock Performance
NYSE:MCK opened at $621.03 on Friday. The firm has a market cap of $77.83 billion, a PE ratio of 28.44, a price-to-earnings-growth ratio of 1.29 and a beta of 0.52. McKesson Co. has a fifty-two week low of $464.42 and a fifty-two week high of $637.51. The business has a 50 day moving average price of $592.91 and a 200-day moving average price of $563.46.
McKesson (NYSE:MCK – Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $8.03 earnings per share for the quarter, missing analysts’ consensus estimates of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. Research analysts predict that McKesson Co. will post 32.77 EPS for the current year.
McKesson Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Monday, March 3rd will be paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date is Monday, March 3rd. McKesson’s payout ratio is 13.00%.
About McKesson
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Read More
- Five stocks we like better than McKesson
- Investing In Automotive Stocks
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- Basic Materials Stocks Investing
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- How to buy stock: A step-by-step guide for beginners
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.